For its third fiscal quarter (ending September 30), Abbott Laboratories (NYSE: ABT) has reported a 0% change in E.P.S. from $0.94 a year ago to $0.94 in the current quarter. For the latest four quarters through September 30, E.P.S. were $7.99 compared to $3.31 a year ago — an increase of 141%.
Recent Price Action
Abbott Laboratories (NYSE: ABT) stock closed at $129.45 on 10/15/25 after a decline of -2.9%. Moreover, exceptionally high trading volume at 260% of normal accompanied the decline. The stock has declined -2.7% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
Abbott Laboratories has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Abbott Laboratories has a slightly negative Power Rating of 36 and a slightly negative Appreciation Score of 31, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment